Lineage Cell Therapeutics
LCTX
107 hedge funds and large institutions have $107M invested in Lineage Cell Therapeutics in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 33 closing their positions.
1,200% more call options, than puts
Call options by funds: $52K | Put options by funds: $4K
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3.49% more ownership
Funds ownership: 40.96% → 44.45% (+3.5%)
2% more capital invested
Capital invested by funds: $105M → $107M (+$2.03M)
7% less funds holding
Funds holding: 115 → 107 (-8)
18% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 33
Top Buyers
| 1 |
BlackRock
New York
|
+$7.33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.07M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.57M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$908K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.9M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.07M |
| 4 |
Jane Street
New York
|
-$792K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$569K |
LCTX Hedge Fund Activity: Q2 2023 in Review
107 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2023, worth a combined $107M — up 1.9% from $105M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of LCTX and 27 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 25 added.
The largest buyer was BlackRock, adding an estimated $7.33M. The largest seller was Millennium Management, exiting entirely with an estimated $2.1M sold.
- 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2023, down from 115 in Q1 2023.
- Funds reported $107M of Lineage Cell Therapeutics stock for Q2 2023, up 1.9% quarter-over-quarter.
- 27 funds opened new Lineage Cell Therapeutics positions in Q2 2023 and 33 closed out, a net change of -6 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2023 was BlackRock, an estimated $7.33M added.
- The largest Lineage Cell Therapeutics seller in Q2 2023 was Millennium Management, an estimated $2.1M sold.
Based on aggregated 13F filings for Q2 2023.